Etomidate is still a valid anesthetic for electroconvulsive therapy

Philip W. Lebowitz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Komatsu et al have recently written that the use of etomidate as an anesthetic induction agent for surgery is associated with increased 30-day mortality and cardiovascular morbidity, compared with propofol. Etomidate has long been recognized assuppressing adrenocortical function and, as an infusion over days, has been indicted in increasing intensive care unit patient mortality. Even in single doses, etomidate causes a reduction in cortisol production, although recovery from single-dose suppression is generally prompt. In prospectively evaluating etomidate as an anesthetic for electroconvulsive therapy, Lebowitz et al, in a pilot study, found that 3 times per week, etomidate did not cause adrenocortical suppression that lasted until the following treatment. The steroid responses did not differ from those of methohexital, and no patient demonstrated evidence of cortisol deficiency. Consequently, concerns raised by Komatsu et al about etomidate's safety seem unwarranted when used for electroconvulsive therapy, and their study's conclusions likely relate to issues with their retrospective methodology.

Original languageEnglish (US)
Pages (from-to)261-262
Number of pages2
JournalJournal of ECT
Volume30
Issue number4
DOIs
StatePublished - Dec 10 2014

Fingerprint

Etomidate
Electroconvulsive Therapy
Anesthetics
Hydrocortisone
Methohexital
Mortality
Propofol
Intensive Care Units
Steroids
Morbidity
Safety

Keywords

  • Adrenocortical suppression
  • ECT
  • Etomidate

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience (miscellaneous)
  • Medicine(all)

Cite this

Etomidate is still a valid anesthetic for electroconvulsive therapy. / Lebowitz, Philip W.

In: Journal of ECT, Vol. 30, No. 4, 10.12.2014, p. 261-262.

Research output: Contribution to journalArticle

Lebowitz, Philip W. / Etomidate is still a valid anesthetic for electroconvulsive therapy. In: Journal of ECT. 2014 ; Vol. 30, No. 4. pp. 261-262.
@article{4c82b2b799e9471abcf28621ee6222cc,
title = "Etomidate is still a valid anesthetic for electroconvulsive therapy",
abstract = "Komatsu et al have recently written that the use of etomidate as an anesthetic induction agent for surgery is associated with increased 30-day mortality and cardiovascular morbidity, compared with propofol. Etomidate has long been recognized assuppressing adrenocortical function and, as an infusion over days, has been indicted in increasing intensive care unit patient mortality. Even in single doses, etomidate causes a reduction in cortisol production, although recovery from single-dose suppression is generally prompt. In prospectively evaluating etomidate as an anesthetic for electroconvulsive therapy, Lebowitz et al, in a pilot study, found that 3 times per week, etomidate did not cause adrenocortical suppression that lasted until the following treatment. The steroid responses did not differ from those of methohexital, and no patient demonstrated evidence of cortisol deficiency. Consequently, concerns raised by Komatsu et al about etomidate's safety seem unwarranted when used for electroconvulsive therapy, and their study's conclusions likely relate to issues with their retrospective methodology.",
keywords = "Adrenocortical suppression, ECT, Etomidate",
author = "Lebowitz, {Philip W.}",
year = "2014",
month = "12",
day = "10",
doi = "10.1097/YCT.0000000000000157",
language = "English (US)",
volume = "30",
pages = "261--262",
journal = "Journal of ECT",
issn = "1095-0680",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Etomidate is still a valid anesthetic for electroconvulsive therapy

AU - Lebowitz, Philip W.

PY - 2014/12/10

Y1 - 2014/12/10

N2 - Komatsu et al have recently written that the use of etomidate as an anesthetic induction agent for surgery is associated with increased 30-day mortality and cardiovascular morbidity, compared with propofol. Etomidate has long been recognized assuppressing adrenocortical function and, as an infusion over days, has been indicted in increasing intensive care unit patient mortality. Even in single doses, etomidate causes a reduction in cortisol production, although recovery from single-dose suppression is generally prompt. In prospectively evaluating etomidate as an anesthetic for electroconvulsive therapy, Lebowitz et al, in a pilot study, found that 3 times per week, etomidate did not cause adrenocortical suppression that lasted until the following treatment. The steroid responses did not differ from those of methohexital, and no patient demonstrated evidence of cortisol deficiency. Consequently, concerns raised by Komatsu et al about etomidate's safety seem unwarranted when used for electroconvulsive therapy, and their study's conclusions likely relate to issues with their retrospective methodology.

AB - Komatsu et al have recently written that the use of etomidate as an anesthetic induction agent for surgery is associated with increased 30-day mortality and cardiovascular morbidity, compared with propofol. Etomidate has long been recognized assuppressing adrenocortical function and, as an infusion over days, has been indicted in increasing intensive care unit patient mortality. Even in single doses, etomidate causes a reduction in cortisol production, although recovery from single-dose suppression is generally prompt. In prospectively evaluating etomidate as an anesthetic for electroconvulsive therapy, Lebowitz et al, in a pilot study, found that 3 times per week, etomidate did not cause adrenocortical suppression that lasted until the following treatment. The steroid responses did not differ from those of methohexital, and no patient demonstrated evidence of cortisol deficiency. Consequently, concerns raised by Komatsu et al about etomidate's safety seem unwarranted when used for electroconvulsive therapy, and their study's conclusions likely relate to issues with their retrospective methodology.

KW - Adrenocortical suppression

KW - ECT

KW - Etomidate

UR - http://www.scopus.com/inward/record.url?scp=84928272836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928272836&partnerID=8YFLogxK

U2 - 10.1097/YCT.0000000000000157

DO - 10.1097/YCT.0000000000000157

M3 - Article

C2 - 25010029

AN - SCOPUS:84928272836

VL - 30

SP - 261

EP - 262

JO - Journal of ECT

JF - Journal of ECT

SN - 1095-0680

IS - 4

ER -